---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-075241"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:16:38.392463+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rezolute to initiate Phase 3 for RZ358 in congenital HI outside US in Q4 2023; FDA restrictions prevent US inclusion

## Summary
- Phase 3 sunRIZE study of RZ358 planned in Europe/ex-US starting Q4 2023; topline results expected 1H 2025.
- FDA maintained age restriction (12+ years) and re-imposed dose cap based on rat toxicology; US inclusion currently infeasible.
- Company evaluating nonclinical studies to address FDA concerns in parallel with ex-US Phase 3; cash $129M sustains ops through Q3 2025.
- Phase 2b RIZE study showed RZ358 generally safe, well-tolerated, and effective in improving hypoglycemia.
- Estimated congenital HI prevalence >10,000 in primary markets; >50% lack adequate treatment.

## SEC filing metadata
- accession: 0001104659-23-075241
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465923075241/0001104659-23-075241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465923075241/tm2319715d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-075241
- JSON: https://secwatch.observer/filing/0001104659-23-075241.json
- Plain text: https://secwatch.observer/filing/0001104659-23-075241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.